Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BLU-451

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Blueprint Medicines

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	BLU-451 Sensitive: C3 – Early Trials BLU-451 Sensitive : C3	BLU-451 Sensitive: C3 – Early Trials BLU-451 Sensitive : C3
EGFR exon 20 insertion	Solid Tumor	EGFR exon 20 insertion	Solid Tumor	BLU-451 Sensitive: D – Preclinical BLU-451 Sensitive : D	BLU-451 Sensitive: D – Preclinical BLU-451 Sensitive : D